MEN1

Chr 11AD

menin 1

Also known as: MEAI, SCG2

This gene encodes menin, a tumor suppressor associated with a syndrome known as multiple endocrine neoplasia type 1. Menin is a scaffold protein that functions in histone modification and epigenetic gene regulation. It is thought to regulate several pathways and processes by altering chromatin structure through the modification of histones. [provided by RefSeq, May 2019]

Primary Disease Associations & Inheritance

Adrenal adenoma, somatic
Angiofibroma, somatic
Carcinoid tumor of lung
Lipoma, somatic
Multiple endocrine neoplasia 1MIM #131100
AD
Parathyroid adenoma, somatic
Multiple endocrine neoplasia 1MIM #131100
AD
UniProtFamilial multiple endocrine neoplasia type I
700
ClinVar variants
141
Pathogenic / LP
1.00
pLI score· haploinsufficient
12
Active trials
Clinical SummaryMEN1
🧬
Gene-Disease Validity (ClinGen)
multiple endocrine neoplasia type 1 · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
141 Pathogenic / Likely Pathogenic· 297 VUS of 700 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Dual constrained — LoF & missense intolerant
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.17LOEUF
pLI 1.000
Z-score 4.71
OE 0.04 (0.010.17)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
3.25Z-score
OE missense 0.53 (0.470.59)
200 obs / 377.7 exp
Constrained

Highly missense-constrained (top ~0.1%)

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.04 (0.010.17)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.53 (0.470.59)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.93
01.21.6
LoF obs/exp: 1 / 27.8Missense obs/exp: 200 / 377.7Syn Z: 0.75

ClinVar Variant Classifications

700 submitted variants in ClinVar

Classification Summary

Pathogenic95
Likely Pathogenic46
VUS297
Likely Benign189
Benign50
Conflicting23
95
Pathogenic
46
Likely Pathogenic
297
VUS
189
Likely Benign
50
Benign
23
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
65
4
26
0
95
Likely Pathogenic
19
19
8
0
46
VUS
6
267
20
4
297
Likely Benign
0
3
66
120
189
Benign
0
1
28
21
50
Conflicting
23
Total90294148145700

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

MEN1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

MEN1-related multiple endocrine neoplasia

definitive
ADLoss Of FunctionAbsent Gene Product
SkinCancer
G2P ↗

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

2 OMIM entries

MENIN 1 ; MEN1
MIM #613733 · *

Adrenal adenoma, somatic

Molecular basis of disorder known

Angiofibroma, somatic

Molecular basis of disorder known

Carcinoid tumor of lung

Molecular basis of disorder known

Lipoma, somatic

Molecular basis of disorder known

Multiple endocrine neoplasia 1

MIM #131100

Molecular basis of disorder known

Autosomal dominant

Parathyroid adenoma, somatic

Molecular basis of disorder known

Multiple endocrine neoplasia 1

MIM #131100

Molecular basis of disorder known

Autosomal dominant
📖
GeneReview available — MEN1
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
Multiple Endocrine Neoplasia Type 1: Latest Insights.
Brandi ML et al.·Endocr Rev
2021Review
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).
Thakker RV et al.·J Clin Endocrinol Metab
2012Review
Multiple Endocrine Neoplasia: Genetics and Clinical Management.
Norton JA et al.·Surg Oncol Clin N Am
2015Review
Guidelines for diagnosis and therapy of MEN type 1 and type 2.
Brandi ML et al.·J Clin Endocrinol Metab
2001Review
Menin in Cancer.
Majer AD et al.·Genes (Basel)
2024Review
Familial pituitary tumors.
Alband N et al.·Handb Clin Neurol
2014Review
MENX.
Pellegata NS·Ann Endocrinol (Paris)
2012Review
Top 10 resultsSearch PubMed ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Neuroendocrine NeoplasmNeuroendocrine Neoplasm of Gastrointestinal TractNeuroendocrine Neoplasm of Lung

Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients

RECRUITING
NCT06523582Universidad Nacional Autonoma de MexicoStarted 2022-08-03
Acute Myeloid LeukemiaAML, AdultAML With Gene Mutations

Revumenib in Combination With 7+3 + Midostaurin in AML

RECRUITING
NCT06313437Phase PHASE1Richard Stone, MDStarted 2024-12-06
RevumenibMidostaurinCytarabine
Acute LeukemiaAdenomatous PolyposisAdrenocortical Carcinoma

Familial Investigations of Childhood Cancer Predisposition

RECRUITING
NCT03050268St. Jude Children's Research HospitalStarted 2017-04-06
Acute LeukemiaAcute Leukemia of Ambiguous LineageAcute Lymphoblastic Leukemia

Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant

RECRUITING
NCT06575296Phase PHASE1City of Hope Medical CenterStarted 2024-12-06
Biospecimen CollectionBone Marrow AspirationBone Marrow Biopsy
Acute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 Mutation

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

RECRUITING
NCT06222580Phase PHASE1Uma BorateStarted 2024-02-20
Biospecimen CollectionBone Marrow Aspiration and BiopsyGilteritinib
Recurrent Acute Leukemia of Ambiguous LineageRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

ACTIVE NOT RECRUITING
NCT05761171Phase PHASE2Children's Oncology GroupStarted 2024-01-08
Biospecimen CollectionBone Marrow AspirationCalaspargase Pegol
Acute Myeloid Leukemia

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

NOT YET RECRUITING
NCT07223814Phase PHASE3Stichting Hemato-Oncologie voor Volwassenen NederlandStarted 2025-12
BleximenibCytarabineDaunorubicin or Idarubicin
Rare DisordersUndiagnosed DisordersDisorders of Unknown Prevalence

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

RECRUITING
NCT01793168Sanford HealthStarted 2010-07
LeukemiaHOX Gene

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

RECRUITING
NCT06229912Phase PHASE2M.D. Anderson Cancer CenterStarted 2024-06-04
Revumenib
Neuroendocrine Carcinoma MetastaticPancreatic Tumors

FTT PET/CT in Pancreatic Neuroendocrine Tumors

RECRUITING
NCT07114939Phase PHASE1Abramson Cancer Center at Penn MedicineStarted 2025-10-01
[18F]FluorThanatrace
Acute Myeloid LeukemiaMixed Lineage Leukemia Gene MutationRefractory AML

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

RECRUITING
NCT05735184Phase PHASE1Kura Oncology, Inc.Started 2023-07-18
ZiftomenibVenetoclaxAzacitidine
Polycythemia VeraEssential ThrombocythaemiaMyelofibrosis

Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History

NOT YET RECRUITING
NCT06923670Phase NAFondazione Policlinico Universitario Agostino Gemelli IRCCSStarted 2025-05-21
NGS testingNGS analysis for mutations in genes involved in familial predisposition to hematological malignancies